Search / Trial NCT06611137

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Launched by SUN YAT-SEN UNIVERSITY · Sep 23, 2024

Trial Information

Current as of December 22, 2024

Recruiting

Keywords

Sbrt Immunotherapy Larynx Preservation Laryngeal Cancer Hypopharynx Cancer

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with advanced laryngeal or hypopharyngeal cancer. The treatment combines a type of targeted radiation therapy called SBRT with a combination of chemotherapy and immunotherapy drugs (specifically Toripalimab, Docetaxel, and Cisplatin). The goal is to see if this combination can safely help preserve the larynx (voice box) while effectively treating the cancer.

To be eligible for this trial, participants need to be between 18 and 70 years old and have specific types of laryngeal or hypopharyngeal cancer. They should also be in good overall health, able to tolerate chemotherapy and immunotherapy, and not have other serious cancers or conditions that would prevent them from participating. If chosen to take part, participants can expect to receive the new treatment and be closely monitored for safety and effectiveness. This trial is currently looking for volunteers, so it’s a great opportunity for those who meet the criteria to contribute to important cancer research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
  • age 18-70
  • PS score 0-1
  • normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
  • Exclusion Criteria:
  • Patients with a combination of other malignant tumours
  • Individuals with contraindications to immunotherapy

About Sun Yat Sen University

Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0